期刊文献+

NSD家族组蛋白甲基化转移酶与肿瘤发生 被引量:2

The NSD Family of Histone Methyltransferase and Tumorigenesis
原文传递
导出
摘要 组蛋白的修饰通过调节染色质结构的疏密程度从而影响基因转录等与DNA有关的生物学功能。NSD蛋白家族(nuclear receptor binding SET domain proteins)(包括NSD1-3)是一组与肿瘤发生相关的组蛋白甲基化转移酶,其中又以NSD2与肿瘤的关系最为密切。近年来的研究发现,NSD2在多发性骨髓瘤、神经母细胞瘤及肝癌等多种肿瘤中高表达,并且相关病人的预后较差。NSD2呈现多种原癌基因的特征:NSD2高表达促进细胞增殖、克隆形成、侵袭能力增强以及肿瘤移植物的生长等。然而,NSD1与NSD3虽然可以与核孔蛋白98 k Da(nucleoporin 98 k Da,NUP98)形成融合蛋白,在部分急性髓性白血病中有致瘤作用,但是它们本身却具有抑癌基因的特点。该文就NSD蛋白家族的最新研究进展作一综述,阐述了NSD蛋白家族在肿瘤发生发展中的作用及潜在的应用前景。 Histone modification regulates gene transcription and other DNA related biological functions through adjusting the structure of the chromatins. The NSD proteins (nuclear receptor binding SET domain proteins), including NSD1-3, are a family of cancer related histone lysine methyltransferases, among which NSD2 is most closely associated with cancer. Recent studies showed that NSD2 was overexpressed in many cancers including multiple myeloma, neuroblastoma, hepatocyte carcinoma, etc. High expression of NSD2 was associated with poor prognosis of many cancer types. NSD2 has properties ofproto-oncogenes, as its overexpression promotes cell proliferation, colony formation, invasion and exograft growth. However, although NSD1 and NSD3 form fusion proteins with nucleoporin 98 kDa (NUP98) in AML and promote tumorgenesis, NSD1 and NSD3 alone behave more like tumor suppressors. Here, we reviewed the current knowledge on NSD family in tumorigenesis and prospect their special value in cancer management.
出处 《中国细胞生物学学报》 CAS CSCD 2015年第5期728-733,共6页 Chinese Journal of Cell Biology
基金 国家自然科学基金(批准号:31260270) 云南省教育厅重点项目(批准号:2011Z113) 云南省科技厅应用基础研究项目(批准号:2011FB078)资助的课题~~
关键词 NSD1 NSD2 NSD3 组蛋白甲基化转移酶 肿瘤 NSD1 NSD2 NSD3 histone methyltransferase neoplasm
  • 相关文献

参考文献45

  • 1Chang C J, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012; 106(2): 243-7.
  • 2Verma SK, Knight SD. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer. Future Med Chem 2013; 5(14): 1661-70.
  • 3Wee S, Dhanak D, Li H, Armstrong SA, Copeland RA, Sims R, et al. Targeting epigenetic regulators for cancer therapy. Ann N YAcad Sci 2014; 1309: 30-6.
  • 4Morishita M, di Luccio E. Cancers and the NSD family of his- tone lysine methyltransferases. Biochim Biophys Acta 2011; 1816(2): 158-63.
  • 5Li Y, Trojer P, Xu CF, Cheung P, Kuo A, Drury WJ, et al. The target of the NSD family of histone lysine methyltransferases de- pends on the nature of the substrate. J Biol Chem 2009; 284(49): 34283-95.
  • 6Jaju RJ, Fidler C, Haas OA, Strickson AJ, Watkins F, Clark K, et al. A novel gene, NSD1, is fused to NUP98 in the t(5;ll) (q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 2001; 98(4): 1264-7.
  • 7Thol F, Kolking B, Hollink IH, Darnm F, van den Heuvel-Eibrink MM, Michel Zwaan C, et al. Analysis of NUP98/NSD1 translo- cations in adult AML and MDS patients. Leukemia 2013; 27(3): 750-4.
  • 8Shiba N, Ichikawa H, Taki T, Park M J, Jo A, Mitani S, et al. NUP98-NSD1 gene fusion and its related gene expression sig- nature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer 2013; 52(7): 683-93.
  • 9Akiki S, Dyer SA, Grimwade D, Ivey A, Abou-Zeid N, Borrow J, et al. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pedi- atric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR. Genes Chromosomes Cancer 2013; 52(ll): 1053-64.
  • 10Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, et al. NUP98/NSD1 char- acterizes a novel poor prognostic group in acute myeloid leuke- mia with a distinct HOX gene expression pattern. Blood 2011; 118(13): 3645-56.

同被引文献18

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部